Are Biosimilars The Next Big Opportunity In India?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Indian biosimilars market is a multi-billion dollar opportunity for Indian and multinational companies to tap into, albeit via different routes, according to a white paper released this month by global consultancy Frost & Sullivan